Neurology

cAPPricorn-1: A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy

The purpose of the study is to evaluate the effect of ALN-APP on measures of Cerebral Amyloid Angiopathy (CAA) disease progression and to characterize the safety, tolerability and pharmacodynamics of ALN-APP in adult patients with sporadic CAA and Dutch-type CAA.

CAPTIVA: Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis

The narrowing of brain arteries is one of the most common causes of stroke worldwide. There is evidence to suggest that antithrombotic medications could reduce the rate of stroke in patients with narrowed brain arteries. This study will compare antithrombotic medication (rivaroxaban or ticagrelor or both) to the standard care antiplatelet medication (clopidogrel).

ENRICH-AF: EdoxabaN for IntraCranial Hemorrhage Survivors with Atrial Fibrillation

The objective of this study is to evaluate whether edoxaban is superior to standard medical therapy in reducing the risk of stroke in high-risk atrial fibrillation patients with previous intracranial hemorrhage.

LAAOS-4: The Fourth Left Atrial Appendage Occlusion Study

Atrial fibrillation is a common condition where the heart’s upper chambers beat too fast and irregularly, reducing pumping efficiency. This can cause blood to pool, increasing the risk of clot formation. If a clot enters the bloodstream, it can block arteries and cause a stroke.

The LAAOS-4 study aims to determine if closing the left atrial appendage with the WATCHMAN FLX™ or FLX PRO™ device, along with Oral Anticoagulant (OAC) medication, is more effective at preventing strokes and blood clots than OAC medication alone.

LIBREXIA-STROKE: A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack

The purpose of this study is to evaluate whether milvexian compared to placebo reduces the risk of recurrent ischemic stroke.

ReMEDy2: Treatment of Acute Ischemic Stroke

This study will evaluate the safety and efficacy of DM199 (rinvecalinase alfa) in treating participants with moderate stroke severity, who present within 24 hours of Acute Ischemic Stroke onset due to small and medium vessel blockages.

SATURN: Statins in Intracerebral Hemorrhage

This study aims to determine whether statin drugs should be continued or discontinued after spontaneous lobar intracerebral hemorrhage (subtype of stroke) and whether the decision to continue/discontinue statins should be influenced by an individual’s APOE genotype.